T cell immunotherapy startup gets $46M Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 18 August, 2025

Big Pharma is doubling down. Startups are going all in. Who’s actually making AI work in drug R&D? Join the debate — online in the morning for everyone and in person for live-only content and a reception in the evening at NYC’s Georgia Room. Choose your pass today.

news Gene therapy startup Kriya Therapeutics gets $313M Novo Nordisk’s Wegovy is the second drug approved in MASH Swedish biotech gets $46M to run early TCR cell therapy clinical trial Pfizer's sickle cell drug candidate fails Phase 3 trial

Principal - Life Science Alexandria Real Estate Equities San Francisco, CA, USA Senior Director of IT Caribou Biosciences, Inc. Berkeley, CA, USA Director Of Business Development, Health And Biomedical Innovation Brown University Providence, RI, USA Senior Patent Counsel Caribou Biosciences, Inc. Berkeley, CA, USA Head of Lab Operations Terray Therapeutics, Inc. Monrovia, CA, USA Principal Scientist, Molecular Design Terray Therapeutics, Inc. Monrovia, CA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Aug 21 2:00pm ET Agentic AI is here: Real-world applications in life sciences & healthcare sponsored by IBM Sep 04 11:00am ET Not just a tool: How AI agents become trial teammates sponsored by Medable Sep 09 11:30pm ET How ctDNA can assist in critical nonoperative management decisions sponsored by Haystack MRD Sep 25 11:00am ET Leveraging acoustic focusing for fast and precise high-parameter flow cytometry panels sponsored by Termo Fisher

Biopharma is grappling with diverging policies between the US, EU, and Asia — including proposed drug pricing reforms in the US and new EU regulations taking effect this year. The need for strategic clarity has never been more urgent. Join us in London — in person and virtually — where we’re bringing together the industry’s most influential voices to chart a path forward.

in case you missed it 1. RFK Jr. says he’s not running for president in 2028, defends top aide 2. Precigen’s rare disease therapy gets full approval from the FDA 3. Scoping the VEGF bispecific landscape: Which large pharma might make the next move? 4. Peer Review Stephen Hahn steps down as CEO of Flagship biotech; A new era at AbbVie partner Gubra 5.